{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:43:08Z","timestamp":1792291388846,"version":"4.4.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejphar.2026.179040","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T06:50:40Z","timestamp":1779864640000},"page":"179040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Combination of Deferoxamine and Deferiprone demonstrates superior efficiency compared to monotherapies in management of cardiac iron overload: Evidence from meta-analysis"],"prefix":"10.1016","volume":"1029","author":[{"given":"Subhangi","family":"Basu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swagatam","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deblina","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annesa","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Chakrabarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praphulla Chandra","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3676-6000","authenticated-orcid":false,"given":"Nishant","family":"Chakravorty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.179040_bib2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5001\/omj.2013.31","article-title":"Side effects of deferasirox iron chelation in patients with beta thalassemia major or intermedia","volume":"28","author":"Al-Khabori","year":"2013","journal-title":"Oman Med. J."},{"key":"10.1016\/j.ejphar.2026.179040_bib3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.35975\/apic.v29i6.2916","article-title":"Comparative efficacy of iron chelation therapies in thalassemia major: a randomized controlled trial","volume":"29","author":"Al-maaroof","year":"2025","journal-title":"Anaesth. Pain Intensive Care"},{"key":"10.1016\/j.ejphar.2026.179040_bib1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3109\/08880018.2013.861046","article-title":"Efficacy and safety of deferasirox in \u03b2-Thalassemia major patients in Iran: a prospective study from a single referral Center in Iran","volume":"31","author":"Alavi","year":"2014","journal-title":"Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ejphar.2026.179040_bib4","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2141.2004.05202.x","article-title":"Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2\u2217 cardiovascular magnetic resonance","volume":"127","author":"Anderson","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejphar.2026.179040_bib5","article-title":"Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2\u2217 MRI in thalassemia maior","volume":"8","author":"Ansari","year":"2017","journal-title":"Caspian J. Intern. Med."},{"key":"10.1016\/j.ejphar.2026.179040_bib6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/thalassrep13030017","article-title":"Understanding the intricacies of iron overload associated with \u03b2-Thalassemia: a comprehensive review","volume":"13","author":"Basu","year":"2023","journal-title":"Thalassemia Reports"},{"key":"10.1016\/j.ejphar.2026.179040_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520934260","article-title":"Assessment of cardiac and liver iron overload by magnetic resonance imaging in patients with thalassemia major: short-term follow-up","volume":"48","author":"Bayav","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.ejphar.2026.179040_bib8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/ajh.25370","article-title":"Long\u2010term improvement in cardiac magnetic resonance in \u03b2\u2010thalassemia major patients treated with deferasirox extends to patients with abnormal baseline cardiac function","volume":"94","author":"Casale","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejphar.2026.179040_bib9","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bcmd.2014.04.006","article-title":"Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients","volume":"53","author":"Cassinerio","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ejphar.2026.179040_bib10","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s00277-012-1480-8","article-title":"Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients","volume":"91","author":"Cassinerio","year":"2012","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ejphar.2026.179040_bib11","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00277-015-2476-y","article-title":"The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent \u03b2-thalassemia in Taiwan","volume":"94","author":"Chang","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ejphar.2026.179040_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172147","article-title":"Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome","volume":"12","author":"de Montalembert","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2026.179040_bib13","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.transci.2019.03.021","article-title":"A 1-year randomized trial of deferasirox alone versus deferasirox and deferoxamine combination for the treatment of iron overload in thalassemia major","volume":"58","author":"Eghbali","year":"2019","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.ejphar.2026.179040_bib14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/ejh.12507","article-title":"Efficacy and safety of a novel combination of two oral chelators deferasirox\/deferiprone over deferoxamine\/deferiprone in severely iron overloaded young beta thalassemia major patients","volume":"95","author":"Elalfy","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ejphar.2026.179040_bib15","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/bloodadvances.2021006778","article-title":"Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years","volume":"7","author":"Elalfy","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejphar.2026.179040_bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.bcmd.2011.03.007","article-title":"Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications","volume":"47","author":"Farmaki","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ejphar.2026.179040_bib17","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2141.2009.07970.x","article-title":"Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major","volume":"148","author":"Farmaki","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejphar.2026.179040_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s13312-016-0821-4","article-title":"Comparative efficacy and safety of oral iron chelators and their novel combination in children with thalassemia","volume":"53","author":"Gomber","year":"2016","journal-title":"Indian Pediatr."},{"key":"10.1016\/j.ejphar.2026.179040_bib19","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jacc.2010.03.083","article-title":"Iron overload cardiomyopathy","volume":"56","author":"Gujja","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2026.179040_bib20","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1097\/MPH.0000000000001269","article-title":"Combination oral chelation in adult patients with transfusion-dependent thalassemia and high iron burden","volume":"41","author":"Hammond","year":"2019","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ejphar.2026.179040_bib21","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/jnci\/djs256","article-title":"Meta-analysis of efficacy of interventions for elevated depressive symptoms in adults diagnosed with cancer","volume":"104","author":"Hart","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179040_bib22","article-title":"Dual echo tfe in \u0392-thalassemia major patients for the assesment of myocardial iron overload","author":"Hazirolan","year":"2009","journal-title":"Diagn. Interv. Radiol."},{"key":"10.1016\/j.ejphar.2026.179040_bib23","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/mrm.21744","article-title":"Myocardial T measurements in iron\u2010overloaded thalassemia: an in vivo study to investigate optimal methods of quantification","volume":"60","author":"He","year":"2008","journal-title":"Magn. Reson. Med."},{"key":"10.1016\/j.ejphar.2026.179040_bib24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.ejphar.2026.179040_bib25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/ejh.12793","article-title":"Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study)","volume":"98","author":"Ho","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ejphar.2026.179040_bib26","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1002\/sim.7411","article-title":"The Hartung-Knapp modification for random-effects meta-analysis: a useful refinement but are there any residual concerns?","volume":"36","author":"Jackson","year":"2017","journal-title":"Stat. Med."},{"key":"10.1016\/j.ejphar.2026.179040_bib27","doi-asserted-by":"crossref","first-page":"912","DOI":"10.4081\/cp.2017.912","article-title":"Combination Iron chelation therapy with deferiprone and Deferasirox in iron-overloaded patients with transfusiondependent \u03b2-thalassemia Major","volume":"7","author":"Karami","year":"2017","journal-title":"Clin. Pract."},{"key":"10.1016\/j.ejphar.2026.179040_bib28","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/bloodadvances.2021004938","article-title":"Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study","volume":"6","author":"Kwiatkowski","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejphar.2026.179040_bib29","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/S2352-3026(20)30100-9","article-title":"Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial","volume":"7","author":"Maggio","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ejphar.2026.179040_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1438611","volume":"15","author":"Mobinikhaledi","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179040_bib31","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.3390\/jcm11072010","article-title":"Safety and efficacy of the new combination iron chelation regimens in patients with transfusion-dependent thalassemia and severe iron overload","volume":"11","author":"Origa","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejphar.2026.179040_bib32","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"n71","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ejphar.2026.179040_bib33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00277-009-0838-z","article-title":"Deferasirox (Exjade) significantly improves cardiac T2\u2217 in heavily iron-overloaded patients with beta-thalassemia major","volume":"89","author":"Pathare","year":"2010","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ejphar.2026.179040_bib34","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1182\/blood-2013-04-497842","article-title":"A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in \u03b2-thalassemia major (CORDELIA)","volume":"123","author":"Pennell","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.179040_bib35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ajh.23876","article-title":"Sustained improvements in myocardial T2\u2217 over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine","volume":"90","author":"Pennell","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejphar.2026.179040_bib36","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjh.15595","article-title":"MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine","volume":"183","author":"Pepe","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejphar.2026.179040_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1532-429X-15-1","article-title":"Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy","volume":"15","author":"Pepe","year":"2013","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"10.1016\/j.ejphar.2026.179040_bib38","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bjh.12987","article-title":"Deferasirox for cardiac siderosis in \u03b2\u2010thalassaemia major: a multicentre, open label, prospective study","volume":"167","author":"Piga","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.ejphar.2026.179040_bib39","first-page":"40","article-title":"Comparative efficacy and safety of oral iron chelators and their novel combination in children with thalassemia","volume":"4","author":"Rao","year":"2022","journal-title":"Int J Acad Med Pharm"},{"key":"10.1016\/j.ejphar.2026.179040_bib40","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/anec.12389","article-title":"Electrocardiographic presentation, cardiac Arrhythmias, and their management in \u03b2-Thalassemia major patients","volume":"21","author":"Russo","year":"2016","journal-title":"Ann. Noninvasive Electrocardiol."},{"key":"10.1016\/j.ejphar.2026.179040_bib41","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.48276","article-title":"Efficacy and safety of combined deferiprone and Deferasirox in iron-overloaded patients: a systematic review","author":"Salem","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.ejphar.2026.179040_bib42","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/bmjebm-2020-111493","article-title":"Framework for the synthesis of non-randomised studies and randomised controlled trials: a guidance on conducting a systematic review and meta-analysis for healthcare decision making","volume":"27","author":"Sarri","year":"2022","journal-title":"BMJ Evid. Based. Med."},{"key":"10.1016\/j.ejphar.2026.179040_bib43","first-page":"221","article-title":"A study to assess the safety and efficacy of oral iron chelators either alone or in combination in patients with thalassemia","volume":"14","author":"Sekar","year":"2024","journal-title":"Int. J. Med. Public Health"},{"key":"10.1016\/j.ejphar.2026.179040_bib44","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1365-2036.2012.05051.x","article-title":"Review article: the iron overload syndromes","volume":"35","author":"Siddique","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2026.179040_bib45","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ejphar.2026.179040_bib46","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ejphar.2026.179040_bib47","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1532-429X-10-12","article-title":"Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction","volume":"10","author":"Tanner","year":"2008","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"10.1016\/j.ejphar.2026.179040_bib48","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3109\/03630269.2010.485120","article-title":"Effect of combined chelation therapy with deferiprone and deferoxamine on left ventricular diastolic function in adult \u03b2-Thalassemia major patients","volume":"34","author":"Tsiapras","year":"2010","journal-title":"Hemoglobin"},{"key":"10.1016\/j.ejphar.2026.179040_bib49","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/08880018.2010.522230","article-title":"The effects of deferasirox on renal, cardiac and hepatic iron load in patients with \u03b2-Thalassemia major: preliminary results","volume":"28","author":"Unal","year":"2011","journal-title":"Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ejphar.2026.179040_bib50","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1179\/1607845412Y.0000000046","article-title":"Iron-chelation therapy with oral chelators in patients with thalassemia major","volume":"18","author":"Uygun","year":"2013","journal-title":"Hematology"},{"key":"10.1016\/j.ejphar.2026.179040_bib51","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3109\/03630269.2015.1064003","article-title":"Five years of Deferasirox therapy for cardiac iron in \u03b2 -Thalassemia major","volume":"39","author":"Vlachaki","year":"2015","journal-title":"Hemoglobin"},{"key":"10.1016\/j.ejphar.2026.179040_bib52","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/vox.13248","article-title":"Effects of dual chelation therapy with deferasirox and deferoxamine in patients with beta thalassaemia major","volume":"117","author":"Zargari","year":"2022","journal-title":"Vox Sang."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926005224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926005224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:11:49Z","timestamp":1784808709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926005224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":52,"alternative-id":["S0014299926005224"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179040","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of Deferoxamine and Deferiprone demonstrates superior efficiency compared to monotherapies in management of cardiac iron overload: Evidence from meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"179040"}}